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Angiotensin-1-converting enzyme (ACE), a zinc metallopeptidase, consists
of two homologous catalytic domains (N and C) with different substrate
specificities. Here we report kinetic parameters of five different forms of
human ACE with various amyloid beta (Ab) substrates together with high
resolution crystal structures of the N-domain in complex with Ab frag-
ments. For the physiological Ab(1–16) peptide, a novel ACE cleavage site
was found at His14-Gln15. Furthermore, Ab(1–16) was preferentially
cleaved by the individual N-domain; however, the presence of an inactive
C-domain in full-length somatic ACE (sACE) greatly reduced enzyme
activity and affected apparent selectivity. Two fluorogenic substrates, Ab
(4–10)Q and Ab(4–10)Y, underwent endoproteolytic cleavage at the Asp7-
Ser8 bond with all ACE constructs showing greater catalytic efficiency for
Ab(4–10)Y. Surprisingly, in contrast to Ab(1–16) and Ab(4–10)Q, sACE
showed positive domain cooperativity and the double C-domain (CC-
sACE) construct no cooperativity towards Ab(4–10)Y. The structures of
the Ab peptide–ACE complexes revealed a common mode of peptide bind-
ing for both domains which principally targets the C-terminal P20 position
to the S20 pocket and recognizes the main chain of the P10 peptide. It is
likely that N-domain selectivity for the amyloid peptide is conferred
through the N-domain specific S20 residue Thr358. Additionally, the
N-domain can accommodate larger substrates through movement of
the N-terminal helices, as suggested by the disorder of the hinge region in
the crystal structures. Our findings are important for the design of domain
selective inhibitors as the differences in domain selectivity are more pro-
nounced with the truncated domains compared to the more physiological
full-length forms.
Database
The atomic coordinates and structure factors for N-domain ACE with Ab peptides 4–10
(5AM8), 10–16 (5AM9), 1–16 (5AMA), 35–42 (5AMB) and (4–10)Y (5AMC) complexes have
been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformat-
ics, Rutgers University, New Brunswick, NJ, USA (http://www.rcsb.org/).
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Ab, amyloid beta; ACE, angiotensin-1-converting enzyme; ACN, acetonitrile; AD, Alzheimer’s disease; CC-sACE, double C-domain of sACE;
Cdom, soluble form of the C-domain of sACE; CHO, Chinese hamster ovary cells; EDDnp, ethylenediamine 2,4-dinitrophenyl; Ndom389,
minimally glycosylated Ndom; Ndom, soluble form of the N-domain of sACE; NT, 3-nitrotyrosine; RAAS, renin-angiotensin-aldosterone
system; sACE, somatic ACE; tACE, human testis ACE; TFA, trifluoroacetic acid.
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Introduction
Angiotensin-1-converting enzyme (ACE, EC 3.4.15.1)
is a zinc peptidase that plays a pivotal role in the
renin-angiotensin-aldosterone system (RAAS) con-
verting angiotensin I to the vasoactive peptide hor-
mone angiotensin II [1,2]. ACE also cleaves the
vasodilatory peptide bradykinin further enhancing
the blood pressure response [3]. Interestingly, in
humans, somatic ACE (sACE) consists of two
catalytically active domains [4,5] (referred to as the
N- and C-domains) that, while very similar in
sequence and structural topology, display differences
in substrate processing abilities [6–8]. In addition to
the cleavage of vasopeptides, ACE is able to cleave
a variety of peptides that are unrelated to its blood
pressure role. While these are perhaps not the most
well-known ACE substrates, many have important
physiological roles. For instance, there exists an
independent brain RAAS that extends its role
beyond fluid and blood pressure homeostasis into
areas such as sexual behaviour, cerebroprotection,
diabetes, psychological disorders and many neurode-
generative diseases including Alzheimer’s disease
(AD) [9–14]. ACE’s specific role in AD is not
entirely clear and is somewhat controversial [15–20].
However, it has been shown that ACE hydrolyses
the amyloid beta (Ab) peptide, the putative causative
agent of AD [20–26].
The Ab peptide is present in soluble and aggre-
gated extracellular masses in the vasculature and
neuronal tissue of AD patients [27,28]. Ab is formed
from the alternate processing of the transmembrane
amyloid precursor protein via sequential cleavage by
the b- and c-secretases [28–31]. The most well-known
toxic form of Ab is 42 residues long, although Ab
also occurs in many truncated variants and in more
soluble forms [32]. These more soluble oligomers
and protofibrils are strongly correlated with
increased toxicity compared to the more structured
fibrils [33–36]. The Ab(1–16) amyloid variant is
formed via both amyloidogenic and non-amyloido-
genic secretion pathways; however, it has a contro-
versial role in AD being indicated as both inert and
cytotoxic [37–39]. The cytotoxic properties are linked
to the metal binding domain of Ab(1–16), known
for its role in producing detrimental reactive oxygen
species and aiding oligomerization on its own and
within the full-length Ab(1–42) [38–41]. Moreover,
Ab(1–16) formation has been found to be upregu-
lated in AD cerebrospinal fluid [42,43]. There is con-
flicting evidence regarding N- and C-domain
selectivity of Ab cleavage by ACE and the enzyme’s
P1 and P10 preference. The general trend of results
indicates that the N-domain alone is more effective
at Ab cleavage, making it more selective, compared
to the C–domain [21,25,26]. However, in sACE the
C-domain appears to have equivalent selectivity to
the N-domain [22,24]. The absolute selectivity and
cooperative interactions between the two domains of
ACE and Ab remain uncharacterized. The N- and
C-domains of ACE have been shown to display neg-
ative cooperativity in substrate hydrolysis [44–46].
While this is observed with many synthetic and nat-
urally occurring peptides, not all substrates displayed
such an effect [46]. Therefore we rigorously investi-
gated the kinetics of Ab peptide metabolism by dif-
ferent full-length and single domain ACE constructs
under defined experimental conditions. We analysed
the kinetics of hydrolysis of Ab(1–16) and two fluo-
rogenic peptides of the N-terminal region of Ab by
the human sACE containing both active sites, full-
length and single domain ACE containing one active
site, and ACE with two tandem C-domains to pro-
vide a biochemical basis for (a) the potential role of
each active site and (b) possible synergistic effects of
the two domains. Furthermore we interrogated
the cleavage site specificity of the ACE enzymes and
the molecular basis of the Ab peptide binding to the
N-domain using high resolution crystal structures
of the enzyme in complex with five soluble Ab
fragments.
Results
Purification of ACE variants
Six human ACE variants were used to examine the
molecular mechanism of domain selectivity and inter-
domain cooperativity towards Ab substrates (Fig. 1).
Human wild-type sACE consists of a cytoplasmic tail,
transmembrane domain and catalytically active N- and
C-domains. Full-length domain knockout variants of
sACE have had the critical zinc coordinating His resi-
dues converted to Lys residues, in the C-domain
(N-sACE) and N-domain (C-sACE), inactivating each
domain respectively. The full-length double C-domain
construct consists of two C-domains in a sACE form
(CC-sACE). The truncated, single domain enzymes are
in essence the C- and N-domains of sACE in soluble
form (referred to as Cdom and Ndom). For all crystal-
lization experiments a minimally glycosylated form of
Ndom (Ndom389) [47] was used as glycosylation hin-
ders the crystallization of ACE. The Ndom389 con-
struct has only three intact glycosylation sites, sites 3,
8 and 9. This is the minimal site occupancy of the
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Ndom required to maintain the structural and func-
tional integrity of the enzyme.
The human sACE, C-sACE, N-sACE, Ndom (in-
cluding Ndom389), Cdom and CC-sACE variants
(Fig. 1) were expressed in mammalian cells and
then purified using lisinopril-sepharose affinity
chromatography. The sACE, C-sACE and N-sACE
constructs are expressed as membrane-bound proteins
and undergo poor ectodomain shedding [48,49].
Hence, these constructs were purified directly from cell
lysate. CC-sACE is also membrane bound but is shed
much more efficiently and so was purified from the
culture medium. All ACE variants were purified to
apparent homogeneity as assessed by SDS/PAGE
(Fig. 2). The sACE proteins migrated at approximately
170 kDa, while the recombinant Ndom and Cdom
migrated with an apparent molecular mass of 100 kDa
and 78 kDa, respectively.
Kinetics of the hydrolysis of b-amyloid peptides
by ACE
We determined the kinetic constants for the hydrolysis
of various Ab peptides by two separate domains of
ACE and full-length ACE variants in order to further
delineate domain selectivity and probe cooperative
effects.
Ab(1–16) was cleaved most efficiently by the trun-
cated Ndom (kcat/Km 18.46 9 10
5
M
1s1), but was
not hydrolysed by the truncated Cdom even after
prolonged incubation times (Fig. 3, Table 1). A similar
trend was found with the full-length sACE constructs
although the kcat/Km for N-sACE was 6-fold lower
(P < 0.05) than that for Ndom. The varying efficien-
cies between N-sACE and C-sACE are due to a differ-
ence in kcat. The CC-sACE construct was investigated
to see if there was any structural or physical effect on
the C-domain of sACE through the presence of
another protein other than the N-domain. Similarly to
the Cdom, CC-sACE processed Ab(1–16) poorly
compared to C-sACE. Although CC-sACE did process
Ab(1–16) the rate was too slow to generate accurate
kinetic constants (Fig. 3, Table 1).
Fluorogenic peptides are widely used in protease
assays. To validate the use of a fluorogenic Ab pep-
tide, we examined the ability of different ACE con-
structs to hydrolyse fluorogenic Ab(4–10) peptides.
The Ab(4–10)Q peptide was hydrolysed very slowly by
both Ndom and N-sACE (kcat/Km 0.22 9 10
5 and
0.09 9 105 M1s1, respectively) (Table 2). However,
the trend of the full-length and truncated ACE con-
structs was similar to the physiological Ab(1–16),
being more selective towards the truncated Ndom.
CC-sACE displayed almost no hydrolysis towards the
Ab(4–10)Q substrate, similar to Ab(1–16) (Fig. 4,
Table 2).
The Ab(4–10)Y fluorogenic peptide was cleaved with
half the catalytic efficiency to Ab(1–16) by Ndom
Fig. 1. Schematic of the ACE constructs
used. The wild-type ACE (sACE) contains
a signal peptide (black box), the two
homologous ectodomains (C-domain is
indicated with black stripes) with the
indicated active site residues necessary
for the coordination of Zn, a stalk region,
transmembrane domain (grey shaded box)
and cytoplasmic region (CR). The
truncated Ndom (dark blue) contains the
signal peptide and the N-domain. The
truncated Cdom (yellow) is essentially the
same as the C-domain in wild-type sACE
only it lacks the transmembrane region
and has the added signal peptide. The
domain inactivated mutants are identical to
sACE except for the mutation of the
catalytic His residues to Lys (white boxes)
in the N-domain (N-sACE) (blue) and C-
domain (C-sACE) (orange). The CC-sACE
(red) construct is a fusion construct of two
tandem copies of C-domain.
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(9.57 9 105 versus 18.46 9 105 M1s1) (Fig. 5,
Table 3). Contrary to the results of Ab(1–16), sACE
hydrolysed Ab(4–10)Y more efficiently (2-fold greater,
P < 0.05) than Ndom; the increase in sACE’s effi-
ciency is due to the larger Ndom Km as their turnover
rates are equivalent. Notably there was a gain in C-
domain activity towards Ab(4–10)Y. This is evident in
the comparable efficiencies between Cdom, C-sACE,
N-sACE and CC-sACE. The C-sACE Km, however, is
2-fold (P < 0.05) larger than its active N-domain coun-
terpart accounting for C-sACE’s slightly lesser effi-
ciency as the kcat values are alike. Interestingly, the
CC-sACE construct cleaved the Ab(4–10)Y with a
higher kcat/Km than N-sACE but lower than the
truncated Ndom. The overall turnover rate for
CC-sACE was much greater than either Cdom or C-
sACE (1.5-fold increase over both, P < 0.05) towards
Ab(4–10)Y.
Cleavage-site analysis of b-amyloid peptides
To determine the bond at which the Ab peptides were
cleaved by the different ACE variants, each substrate
was incubated under the stated assay conditions and
the peptide products were purified for MALDI-TOF
MS analysis. For the Ab(4–10)Q and Ab(4–10)Y, pep-
tides with m/z = 694.3 were identified (Table 4). This
corresponds to the N-terminal o-aminobenzoyl (Abz)-
Fig. 2. SDS/PAGE of the purified ACE variants. The affinity-purified preparations of recombinant human ACE (approximately 10 lg of protein
each) were analysed by SDS/PAGE as described in Experimental procedures. Molecular mass markers (kDa) are indicated on the left.
Fig. 3. Graphical representation of the overall kinetic efficiency of
Ab(1–16). The data indicate hydrolysis of Ab(4–10)Q by truncated,
full-length and wild-type ACE constructs (error bars indicate the
fractional error of the ratio; n = 3; colour coding as in Fig. 1).
Table 1. Kinetic parameters of Ab(1–16) (H-DAEFRHDSGYEVHHQK-OH) hydrolysis by different ACE variants/molecules. Error is represented
as standard error of the mean (SEM) barring the kcat/Km values where the error represents the fractional error of the ratio; n = 3. ND, not
determined.
Enzyme kcat/Km (M
1s1 9 105) kcat (s1) Km (lM) Vmax E (pmol)
Ndom 18.46  0.72 39.30  0.47 21.35  0.21 0.49  0.02 0.013
N-sACE 3.21  0.72 11.03  1.62 34.20  5.90 0.55  0.08 0.050
sACE 2.36  0.37 8.37  0.90 35.20  4.03 1.00  0.19 0.120
C-sACE 0.17  0.04 0.67  0.08 42.36  9.57 1.15  0.14 1.750
CC-sACE ND ND ND ND ND
Cdom ND ND ND ND ND
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FRHD peptide. Thus, both Ab(4–10) peptides were
endoproteolytically cleaved at the Asp7-Ser8 bond.
The Cdom and CC-sACE cleavage sites were not anal-
ysed as there was negligible hydrolysis of the Ab pep-
tides by these ACE variants under kinetic assay
conditions. Hydrolysis of Ab(1–16) by all the ACE
variants except Cdom yielded peptides with m/z
ratios of 1698.6 (Ndom), 1698.7 (N-sACE, C-sACE,
CC-sACE) and 1698.8 (sACE) within kinetic assay
parameters. These peptides correspond to the N termi-
nus Ab(1–14) (DAEFRHDSGYEVHH) with a calcu-
lated mass of 1698.7 (Table 4). This indicates that Ab
(1–16) is cleaved at a different bond, namely His14-
Gln15. To determine if the Ab(1–16) is further
degraded over time by all forms of ACE, 36.5 lM of
Ab(1–16) was incubated for 24 h (Table 5). Interest-
ingly, the mass of the initial cleavage intermediate Ab
(1–14), 1698.7 m/z, was present across all ACE con-
structs except for N-sACE. However, the Ab(1–12)
(DAEFRHDSGYEV) peptide was only generated by
the sACE mutants (expected m/z of 1325.6). The corre-
sponding C-terminal peptide, Ab(12–16), with an
expected m/z of 648.3 was detected in both Cdom and
Ndom digests as well as in sACE and C-sACE, but
not N-sACE or CC-sACE. The Ab(1–12) product is
probably hydrolysed faster by the Cdom, Ndom and
wild-type sACE. Overall, there appears to be no
absolute domain preference for any specific P1 and P10
residues, similar to the hydrolysis for 15 min. The Ab
(1–7) cleavage site is also found across constructs bar-
ring N-sACE and CC-sACE. These results indicate
that the hydrolysis of Ab(1–16) by both domains of
ACE is not limited or specific, and that under certain
conditions the C-domain does hydrolyse Ab peptides.
Crystal structures of N-domain in complex with
b-amyloid peptides
Crystallization trials were performed to analyse the
molecular interactions of Ndom389 with Ab. While
Ndom389 co-crystals with Ab(1–42) could not be
obtained, trials with shorter Ab fragments, namely Ab
(4–10), Ab(10–16), Ab(1–16), Ab(35–42) and Ab(4–10)Y,
were successful in solving high resolution (1.5–1.9 A)
structures of the complexes (Table 6).
Overall, the structure of Ndom389 did not show any
major conformational change upon peptide binding.
The previously observed hinge motion of the N-term-
inal helices [47] was slightly more pronounced in some
Table 2. Kinetic parameters of Ab(4–10)Q (Abz-AbFRHDSG(Q)-EDDnp) hydrolysis by different ACE variants/molecules. Error is represented
as standard error of the mean (SEM) barring the kcat/Km values where the error represents the fractional error of the ratio; n = 3. ND, not
determined.
Enzyme kcat/Km (M
1s1 9 105) kcat (s1) Km (lM) Vmax E (pmol)
Ndom 0.22  0.04 0.48  0.04 22.20  3.23 0.29  0.02 0.60
N-sACE 0.09  0.01 0.36  0.02 42.43  3.92 3.23  0.20 9.00
sACE 0.03  0.01 0.06  0.01 22.90  3.45 0.09  0.01 1.50
C-sACE 0.08  0.02 0.08  0.01 11.50  3.03 0.12  0.01 1.50
CC-sACE ND ND ND ND ND
Cdom ND ND ND ND ND
Fig. 4. Graphical representation of the overall kinetic efficiency of
Ab(4–10)Q. The data indicate hydrolysis of Ab(4–10)Q by truncated,
full-length and wild-type ACE constructs (error bars indicate the
fractional error of the ratio; n = 3; colour coding as in Fig. 1).
Fig. 5. Graphical representation of the overall kinetic efficiency of Ab
(4–10)Y. Bar graphs represent the hydrolysis of Ab(4–10)Y by
truncated, full-length and wild-type ACE constructs (error bars indicate
the fractional error of the ratio; n = 3; colour coding as in Fig. 1).
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of the molecules and resulted in a larger asymmetric
unit (a = 73 A, b = 102 A, c = 114 A; a = 85°,
b = 86°, c = 81°) with four Ndom389 chains, still in
space group P1, for the Ab(4–10), Ab(10–16), Ab(1–16)
complexes (Table 6). The structures with Ab(35–42)
and Ab(4–10)Y were in the same crystallographic cell as
previously reported for Ndom389 with two chains per
asymmetric unit in P1 (a = 73 A, b = 77 A, c = 83 A;
a = 89°, b = 64°, c = 75°). The degree of movement
appeared limited and could not be correlated to the size
of the substrates or bound peptides, but caused visible
disorder in the N-terminal region of Ndom389 and is
highlighted by higher B factors (Fig. 6A).
In each of the structures, electron density was clearly
observed in the S0 side of the Ndom389 catalytic pocket
for what corresponds to a dipeptide. Electron density
maps for the side chains of sites P10 and P20 of the pep-
tides were interpreted as the products of the prolonged
reactions of Ab cleavage by Ndom389 (Fig. 6C). The
carboxy-dipeptide residues of Ab(35–42) and Ab(4–10)
Y were visible, Ile41-Ala42 and Gly9-3-nitrotyrosine
(NT) 10 respectively. Both Ab(4–10) and Ab(1–16) pre-
sented the Asp7-Ser8 residues. The structure of
Ndom389 with Ab(10–16) was unique in offering two
alternative dipeptides, each present in two of the chains
forming the asymmetric unit, and corresponding to
Glu11-Val12 and Gln15-Lys16. Coincidentally, the Ab
(10–16) structure also showed unusual ion coordination
in proximity to the binding site. In the presence of
Glu11-Val12 a cation is octahedrally coordinated by
Glu262, Asn263 and Asp354 of Ndom389 along with
three water molecules, while the same residues are
involved in cationic interaction with only two water
molecules when Gln15-Lys16 is bound. The ion coordi-
nation was carefully analysed in each case using the
CMM validation server [50] and interpreted as calcium
and sodium ions, respectively. Both are present in the
crystallization conditions but are unlikely to have any
physiological role and have not been observed in any
of the other N-domain crystal structures.
Mode of peptide binding in N-domain S0 pockets
The crystal structures of Ndom389 in complex with
the Ab fragments present a common mechanism of
peptide binding within the S0 catalytic pocket
(Fig. 6B). The Ndom389 essentially recognizes the
main chain of the peptides through seven hydrogen
bonds. The P10 position interacts with the main chain
of Ala332 and the side chains of Glu362, His491 and
His331. The S20 pocket is composed of Gln259,
Lys489 and Tyr498 whose polar side chains anchor the
carboxy-terminal end of the peptide. Furthermore, a
network of water molecules was also observed in all
Table 3. Kinetic parameters of Ab(4–10)Y (Abz-FRHDSG) hydrolysis by different ACE variants/molecules. Error is represented as standard
error of the mean (SEM) barring the kcat/Km values where the error represents the fractional error of the ratio; n = 3.
Enzyme kcat/Km (M
1s1 9 105) kcat (s1) Km (lM) Vmax E (pmol)
Ndom 9.57  0.33 20.30  0.62 21.20  0.31 4.62  0.14 0.228
N-sACE 4.61  0.46 3.87  0.09 8.56  0.83 0.44  0.01 0.113
sACE 22.67  6.40 28.70  5.81 12.60  2.48 0.90  0.18 0.031
C-sACE 1.83  0.18 6.95  1.39 38.10  0.10 1.57  0.09 0.226
CC-sACE 6.33  0.98 12.70  1.16 20.30  2.55 0.90  0.08 0.071
Cdom 2.30  0.87 5.33  0.76 27.23  9.52 4.45  0.63 0.835
Table 4. Ab cleavage products produced from ACE hydrolysis. Observed [M + H]+ ions of the peptide products generated by endoprotease
and exoprotease action of the various ACE constructs on the Ab(1–16), Ab(4–10)Q and Ab(4–10)Y substrates. ND, not determined.
Peptide residues Calculated m/z
Observed m/z
Ndom N-sACE sACE C-sACE CC-sACE Cdom
Ab(1–16)
Substrate DAEFRHDSGYEVHHQK 1954.9 1954.8 1954.8 1954.8 1954.8 1954.8 1954.8
Product DAEFRHDSGYEVHH 1698.7 1698.6 1698.7 1698.8 1698.7 1698.7 ND
Ab(4–10)Q
Substrate Abz-FRHDSG(Q)-EDDnp 1191.5 1191.5 1191.5 1191.5 1191.5 ND 1191.7
Product Abz-FRHD 694.3 694.3 694.3 694.3 694.3 ND ND
Ab(4–10)Y
Substrate Abz-FRHDSG-(NT) 1064.4 1064.4 1064.4 1064.4 1064.4 ND ND
Product Abz-FRHD 694.3 694.3 694.3 693.3 694.3 ND ND
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structures that further mediates interaction of the pep-
tides’ main chain with residues Ala332, Glu362,
Tyr501 and Lys489 of Ndom389 (Fig. 7). The N-term-
inal groups of the peptides are held in close proximity
to the zinc ion via two coordinating water molecules.
Additional and more specific contacts were observed
with peptides Asp7-Ser8 where the side chain of
Thr358 makes a hydrogen bond with the acidic group
of Asp7, and a water-mediated bond exists between
Gln259 and the Ser8 side chain (Fig. 7). Interestingly
the two alternative peptides seen within the structure
of Ab(10–16) show similar contacts at the P10 position
with the longer side chain of Glu11 or Gln15 able to
make direct contact with Ala332 and two water-
mediated interactions with Gln355 (Fig. 7). The side
chain of residues at P20 may be held in position by the
surrounding hydrophobic residues Phe435, Tyr501 and
Phe505. Additionally, the Lys16 e-amino group is
within distance (5.5 A) of a potential cation–p interac-
tion with Phe435. In the case of Ab(4–10)Y, the larger
nitrotyrosine fits well within the S20 pocket. The addi-
tional nitro group is within hydrogen-bond distance of
Gln259 and the hydroxyl group can make water-
mediated interactions further down the catalytic chan-
nel with residues Asp393 and Glu431. Electron density
was observed to be weaker in both molecules of the
asymmetric unit for the nitrotyrosine which may be
indicative of some flexibility (Fig. 7).
Discussion
In order to understand the potential differences
between the two domains of ACE and their synergy
in full-length sACE we have investigated the
metabolism of the Ab peptide by single and double
domain recombinant ACE forms. Previous studies
have noted potential discrepancies in kinetic data and
a lack of substrate specificity based on different
sources and forms of ACE [46,51]. Thus, all of the
constructs were purified from one cell line of Chinese
hamster ovary (CHO) cells and assay conditions were
as physiological as possible.
The Ab(1–16) peptide was cleaved at the His14-
Gln15 bond by all the ACE constructs in our kinetic
experiments, in contrast to the full-length Ab(1–42)
where multiple cleavage sites have been identified for
ACE [20,22–26]. The Ab(1–16) cleavage site at His14-
Gln15 is typical of ACE’s exoprotease action, cleaving
the penultimate C-terminal peptide bond. This type of
cleavage has been observed in previous studies with
other amyloid peptides [23,24] and was also observed
in the crystal structures of the N-domain in complex
with all the Ab fragments tested. Based on the MS
analysis of this study (Tables 4 and 5), the primary
cleavage of Ab(1–16) occurs between residues His14
and Gln15 and was also observed in the Ndom-Gln15-
Lys16 crystal structure of Ab(10–16) (Fig. 6C).
Surprisingly the crystal structure of N-domain with
Ab(10–16) also presented an alternative cleavage site
at Tyr10-Glu11, which is probably the result of succes-
sive dipeptidyl cleavages of the Ab fragment by the N-
domain during crystal growth. Further degradation
was also observed with Ab(4–10) and Ab(1–16) which
actually presented residues Asp7-Ser8 in the structures,
indicative of a His6-Asp7 cleavage site. In contrast to
the suggested crystal structure cleavage site, consecu-
tive cleavage sites of Ab and cleavage of the Asp7-Ser8
site, Ab(1–7) product, were found after prolonged incu-
bation of Ab(1–16) with both N- and C-domain forms
of ACE (Table 5). However, Ab(1–16) hydrolysis at
Table 5. Ab cleavage products from prolonged ACE hydrolysis. The observed cleavage product [M + H]+ ions generated by the various ACE
constructs on the Ab(1–16) substrate over a 24-h period. ND, not determined.
Amyloid peptide Peptide residues Calculated m/z
Observed m/z
Ndom N-sACE sACE C-sACE CC-sACE Cdom
Ab(1–16) DAEFRHDSGYEVHHQK 1954.8 1954.8 1954.8 1954.8 1954.8 1954.8 1954.8
N-terminal products
Ab(1–14) DAEFRHDSGYEVHH 1698.7 1698.7 ND 1698.7 1698.7 1698.6 1698.7
Ab(1–12) DAEFRHDSGYEV 1424.6 1424.6 1424.6 1424.6 1424.6 1424.6 1424.6
Ab(1–11) DAEFRHDSGYE 1325.5 ND 1324.5 ND 1325.5 1325.5 ND
Ab(1–7) DAEFRHD 889.3 889.3 ND 889.3 889.3 ND 889.3
Ab(1–6) DAEFRH 774.4 ND ND ND 774.4 ND ND
Ab(1–5) DAEFR 637.3 637.3 ND 637.3 637.3 637.3 637.3
C-terminal products
Ab(2–16) AEFRHDSGYEVHHQK 1839.8 ND ND ND ND ND 1839.8
Ab(4–16) FRHDSGYEVHHQK 1639.7 1639.7 ND ND ND ND ND
Ab(12–16) VHHQK 648.3 648.3 ND 648.3 648.3 ND 648.3
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His6-Asp7 was only seen after a 24 h incubation with
C-sACE and no N-domain constructs generated this
hydrolysis product (Table 5). It is plausible that the
N-domain constructs degraded it faster after 24 h and
thus it was not detected. Combined, the MS analysis
and crystal structures of the peptides generated by
digestion of Ab(1–16) with Ndom showed that it
undergoes both endoproteolytic and exoproteolytic
cleavage with prolonged incubation (Table 5).
Fluorogenic ACE substrates have been widely used
to investigate the mechanism of substrate processing
and inhibitor binding [7,45,52]. The kinetic assays
indicated that both fluorogenic peptides were endopro-
teolytically cleaved at the previously identified Asp7-
Ser8 bond [20]. Again, the cleavage site was consistent
across all ACE variants. This is in contrast with the
crystal structure of the Ndom389–Ab(4–10)Y complex
that presented Gly9-NT10, the expected product of the
dipeptidylpeptidase activity. Interestingly, previous
assays on ACE fluorescence resonance energy transfer
substrates indicate that the large C-terminal ethylene-
diamine 2,4-dinitrophenyl (EDDnp) groups usually
occupy the S20 pocket and cleavage would take place
one residue away from this acceptor group [7], in
accordance with the crystal structure. In our assays,
cleavage was consistently three residues from the
EDDnp and NT groups which are relatively similar in
charge and size. These results offer evidence that the
fluorogenic peptide may thus be subjected to either
endoproteolytic activity or classical dipeptidylpeptidase
activity depending on the environmental conditions.
Further work is required to understand the extent of
ACE’s endoproteolytic capabilities.
Both biochemical and structural data show the abil-
ity of ACE to cleave peptides of diverse length and
composition. Although the crystal structures with
Table 6. Crystallographic statistics of the structures of Ndom389 in complex with Ab fragments. Rmerge = ΣΣi|Ih  Ihi|/ΣΣiIh, where Ih is the
mean intensity for reflection h. Rpim = Σh(1/nh  1) Σl |Ihl  Ih|/ΣhΣl(Ih). Rcryst = Σ‖Fo|  |Fc‖/Σ|Fo|, where Fo and Fc are measured and
calculated structure factors, respectively. Rfree = Σ‖Fo|  |Fc‖/Σ|Fo|, calculated from 5% of the reflections selected randomly and omitted
during refinement.
Ndom389-Ab(4–10) Ndom389-Ab(10–16) Ndom389-Ab(1–16) Ndom389-Ab(35–42) Ndom389-Ab(4–10)Y
Resolution (A) 1.90 1.80 1.80 1.55 1.65
Visible peptide D7-S8 E11-V12/Q15-K16 D7-S8 I41-A42 G9-(NT)
Space group P1
Cell dimensions (A; a, b, c);
angle (°; a,b,c)
Molecule/AU
73.4, 101.8, 114.4;
85.2, 86.1, 81.4
4
73.3, 101.8, 113.9;
85.0, 85.6, 81.9
4
73.3, 101.7, 114.1;
85.1, 85.6, 81.3
4
73.0, 76.9, 83.2;
88.6, 64.1, 75.2
2
73.0, 76.5, 83.2;
88.8, 64.2, 75.6
2
Total/unique reflections 384,870/293,455 929,478/291,734 461,830/281,258 324,307/200,050 520,452/172,512
Completeness (%) 93 (84)a 97 (95.7)a 94 (82)a 88 (56)a 92 (64)a
Rmerge
a 7.1 (43.8) 12.0 (76.3) 6.1 (46.0) 4.2 (44.4) 8.1 (70.6)
Rpim
a 7.1 (43.8) 7.9 (49.7) 6.0 (45.9) 4.2 (44.4) 5.4 (49.8)
I/r(I)a 5.8 (1.4) 5.3 (1.4) 6.8 (1.4) 7.5 (1.4) 6.4 (1.3)
CC(1/2) 0.996 (0.816) 0.993 (0.325) 0.998 (0.635) 0.993 (0.565) 0.995 (0.318)
Rcryst 18.5 19.7 18.0 15.8 20.8
Rfree 22.4 22.9 21.0 18.1 24.1
rmsd in bond lengths (A) 0.016 0.012 0.011 0.014 0.011
rmsd in bond angles (°) 1.34 1.40 1.34 1.40 1.33
B-factor statistics (A2)
Protein all atoms 27.4/24.8/22.2/23.1 29.3/26.3/24.3/27.0 26.5/23.3/21.2/23.4 33.0/37.8 27.9/31.0
Protein main chain atoms 26.4/23.7/21.1/22.3 28.4/25.2/23.4/26.2 25.2/22.1/20.0/22.3 30.8/35.4 26.7/29.9
Protein side chain atoms 28.4/25.8/23.2/23.9 30.2/27.3/25.2/27.9 27.7/24.6/22.4/24.5 35.2/40.1 29.1/31.1
Peptide atoms 26.0/23.5/24.6/23.3 27.5/23.5/21.9/28.1 27.4/27.3/23.5/26.3 28.4/28.9 41.7/44.6
Solvent atoms 29.7 31.0 30.9 44.8 35.3
Zn2+/Cl ions 16.7/16.2 19.2/19.7
(Na+ 33.5/Ca2+ 35.2)
17.5/16.7 25.5/26.9 19.9/21.5
Glycosylated
carbohydrate atoms
48.6 54.1 47.7 67.3 58.9
Ramachandran statistics (MOLPROBITY)
Favoured 98% 98% 98% 98% 98%
Outliers 0.2% 0.2% 0.2% 0.2% 0.2%
PDB code 5am8 5am9 5ama 5amb 5amc
a Values in parentheses refer to the highest resolution shell.
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N-domain only presented dipeptide fragments, this has
facilitated our understanding of the enzyme’s broad
catalytic activity. This is explained by a common mode
of peptide binding to N-domain, which principally tar-
gets the C-terminal P20 position to the S20 pocket and
recognizes the main chain of the P10 peptide. This
mechanism is reminiscent of C-domain binding to
angiotensin II and the bradykinin potentiating peptide
b (BPPb) [53]. The residues involved in binding within
the S0 pockets are conserved in both ACE domains.
The N-domain selectivity for Ab is therefore most
probably conferred through interactions with the non-
prime binding site [47,53]. Additionally, the N-domain
should be able to accommodate larger substrates
through movement of the N-terminal helices, as sug-
gested by the disorder of the hinge region in the crys-
tal structures and in parallel with the observed ‘open’
conformation of C-domain when bound to BPPb.
Although the chloride ion is expected to play a role in
substrate binding and domain selectivity [54], the
structures presented here did not provide any further
evidence of this.
In addition to the putative shared mode of peptide
recognition, the multiple fragments, observed across
all high resolution structures, displayed some common
interactions. Two groups can be distinguished at P10
where peptides with longer polar side chains (i.e.
Asp7, Glu11 and Gln15) can make hydrogen bonds
with Ala332 or Thr358 of Ndom389. Noticeably,
Thr358 is a residue unique to the N-domain found at
the entrance of S20 pocket and may drive selectivity to
a degree. Second, hydrophobic residues, such as Ile41,
at the P10 position of the substrate have also been
shown to be better cleaved by both domains of ACE
[7]. The S10 and S20 pocket offers strong hydrophobic
interactions for the dipeptides Glu11-Val12, Ile41-
Ala42 and the Gly9-NT10 of Ab(1–16), Ab(1–42) and
Ab(4–10)Y, respectively. Furthermore, a longer polar
side chain may also be stabilized by electrostatic inter-
actions (e.g. Lys16) deeper in the S20 pocket as well as
through a network of water molecules as with the
nitrotyrosine group of Ab(4–10)Y.
Interestingly, N-domain selectivity is affected in the
full-length forms of ACE across all substrates. That is,
Fig. 6. Structures, binding modes and interactions of Ab peptide fragments with the N-domain of ACE. (A) Overall structure of Ndom389
coloured in a B-factor spectrum (white, low; red, high) to highlight the hinge region of the N-terminal domain ‘capping’ the catalytic channel.
The bound dipeptide is shown in purple, the catalytic zinc ion as a grey sphere. (B) Close-up view of the catalytic site of the Ndom389 in
complex with a bound dipeptide. The dipeptide, modelled as Ala-Ala, reflects the common mechanism of binding observed in all complex
structures with Ab fragments. The dipeptide is shown in purple and the Ndom389 residues involved in binding are represented as sticks.
The spheres represent the zinc ion (in grey) and water molecules (in red). (C) Portions of the Fourier electron density map at the site of the
bound peptides. The map was generated using REFMAC5 [74] and corresponds to the difference weighted 2mFo  DFc density map,
contoured at 1.0r level, in which the peptide atoms were omitted.
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the sACE with inactivated C-domain has lower kcat val-
ues for both Ab(1–16) and Ab(4–10)Q than N-domain.
This decrease in turnover rate substantially reduces the
N-domain selectivity of the full-length knockouts. The
sACE form appears to improve the interaction of the Ab
(4–10)Y with the N-domain of N-sACE and slow the
turnover rate. The opposite is true for Ab(4–10)Q.
Despite a general decrease in selectivity of the
N-sACE, our results indicate that amyloid peptides are
far more N-domain selective in the current optimal
C-domain conditions (higher NaCl concentrations).
However, in cells expressing Ab there was no overall
difference in the hydrolysis of Ab between C-sACE,
N-sACE and sACE [22]. This is probably due to the
fact that the C-domain of sACE might only hydrolyse
Ab effectively when the full-length protein is anchored
in the cell membrane [22].
The two active sites within human and bovine sACE
exhibit negative cooperativity with synthetic tripeptide
substrates [44,45,55]. Further work with physiological
substrates and human ACE enzymes showed a similar
result for angiotensin I and angiotensin-(1-7) but not
angiotensin-(1-9), implying that different substrates
result in varying synergistic effects of the two domains
[46]. Similar to other kinetic observations with physio-
logical substrates, such as angiotensin-(1-9) and brady-
kinin, the degree of cooperativity between domains is
considerably less than many synthetic peptides
observed previously [46,56]. The sACE CC-domain
enzyme possessed a catalytic ability per active site sim-
ilar to the individual domains, indicating an additive
effect between the two C-domains with Ab(4–10)Y
substrate.
Given the discrepancy between the magnitude of
selectivity of the truncated domains and the sACE
forms, there are most certainly cooperative effects tak-
ing place with regard to the Ab substrate. The equiva-
lent affinity of the truncated and full-length constructs
to Ab(1–16) and the largely varying turnover rates
suggest a close interaction between the two domains
and the binding and hydrolysis of their individual
active sites. The cooperative effects of the two domains
towards Ab(1–16), overall, are negative. Due to the C-
domain’s poorer hydrolysis of Ab we can infer that
Fig. 7. Mechanism of Ab fragment binding to the N-domain. Schematics of peptide binding to the N-domain. Interactions were calculated
with LIGPLOT+ [77]. The two alternative peptides for Ab(10–16) are included with Glu11-Val12 and Glu15-Lys16 observed in chains A, D and B,
C respectively.
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the C-domain appears to negatively regulate the N-
domain in sACE. This is also true for the Ab(4–10)Q
substrate, although to a much lesser extent. There is a
large shift in both level of cooperativity and type of
cooperativity [see Ab(4–10)Y below] on comparing the
truncated domains to the full-length knockouts. For
instance, the magnitude of the Ab(1–16) negative
cooperative effect decreases on comparing the trun-
cated domains to the sACE constructs, whereas Ab
(4–10)Q has no shift. The positive effect of the
N-domain can be illustrated through C-sACE. Here,
C-sACE exhibited improved activity compared to the
truncated Cdom for all Ab substrates, suggesting that
the N-domain is critical for this synergistic effect to
occur. This notion is further supported by the poor
activity of the CC-sACE and its interaction with both
Ab(1–16) and Ab(4–10)Q, confirming that the mere
presence of another domain did not improve the
C-domain hydrolysis of Ab peptides. Previously, we
showed that the presence of the N-domain had regula-
tory effects on hydrolysis of substrates Cbz-Phe-His-
Leu and (Abz)-LFK(Dnp)-OH [55]. Taken together,
these data suggest that the effects of domain interac-
tions could be influenced by the type of substrate.
The cooperativity in the sACE molecules, however,
was altered by the presence of Ab capping groups.
When one takes the truncated domains into account
there is a negative effect on the activity of sACE. On
examination of the N-sACE and C-sACE constructs, a
positive form of cooperativity is now found towards
Ab(4–10)Y. The two catalytically active domains,
binding and hydrolysis, are affected by both the struc-
tural arrangement and the activity of their respective
active sites. This could be ascribed to the fact that
EDDnp quenchers require attachment of a Gln or Glu
residue, both of which could alter selectivity and inter-
domain cooperativity due to the length and polarity of
their side chains.
Based on our results and the synergistic effect that
the C-domain exerts on the N-domain, the C-domain
activity is likely to be important in vivo. Oba et al.
[21] discovered that the larger Ab(1–40) substrate did
not out-compete smaller substrates like hippuryl-L-his-
tidyl- L-leucine, suggesting that the structure of the C-
domain was not conducive to binding of large Ab
peptides. This observation is supported by the archi-
tecture of the central cavity found in tACE (human
testis ACE, C-domain equivalent) crystal structure
and the chloride-dependent substrate interactions
[54,57]. The latter study, however, was performed on
recombinant truncated domains only. It is also impor-
tant to note that Ab occurs in many forms. In this
study we examined the physiological substrate Ab(1–
16), which is over-secreted in AD [42], contains the
metal binding domain [41,58], forms soluble dimers
[59] and may have metal associated toxic effects
[38,59,60]. Smaller Ab molecules, like Ab(1–16), may
have better access to the C-domain. Indeed, the C-
domain of sACE most certainly has some Ab affinity,
as is evident from the mass spectrometry and kinetic
data on Ab(1–16) and the fluorescence resonance
energy transfer Ab(4–10)Q and Ab(4–10)Y peptides.
One might speculate that the structure of the C-
domain in sACE is more open due to the physical,
and specific, presence of the N-domain. The N-
domain, possibly, stretches out the flexible lid of
helices a1–a3 in the C-domain making substrate access
more efficient [61]. Fluorogenic peptides may not nec-
essarily be the best at indicating selectivity as the
addition of artificial groups on either end bias domain
specificity based on their size, charge and additional
amino acids required to attach them [7,62]. It is also
possible for these groups to stabilize an interaction
that would not necessarily take place [62] such as the
ones observed in the crystal structure where the
nitrotyrosine group of Ab(4–10)Y offers a number of
additional interactions.
In summary, we have assessed the domain selectivity
and cooperativity of Ab peptide hydrolysis. This fur-
ther emphasizes the dynamic roles of the two domains
of sACE in substrate processing. This dynamism is not
conserved across all ACE substrates, but rather
appears dependent on the nature of the substrate itself.
Our study provides further evidence of both endopro-
teolytic and classical dicarboxypeptidase activities of
ACE on Ab peptides. The crystal structures presented
also offer a molecular framework to better understand
peptide binding to the N-domain.
Experimental procedures
Enzymes
For single, soluble enzymatic domains, a modified tACE
construct, tACED36NJ, that lacks the transmembrane
region and unique 36 amino acid N terminus (and is there-
fore identical to the sACE C-domain; referred to as Cdom)
had been generated previously [63]. A soluble form of the
N-domain, consisting of amino acids 1–629 of sACE (re-
ferred to as Ndom), in vector pECE was obtained from S.
Danilov (University of Illinois at Chicago, IL, USA) and
was cloned into sequencing vector pBlueScript SK+ (Invit-
rogen, Carlsbad, CA, USA) as previously described [61,64].
For all crystallization experiments a minimally glycosylated
form of the soluble N-domain (Ndom389) was expressed
and purified as previously described [47].
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The full-length domain knockouts of sACE, both in
pECE, were obtained from V. Dive (CEA, France) and
were constructed by Wei et al. [5] through site directed
mutagenesis [65]. For the construction of the N-sACE, the
His361 (CAT) and His365 (CAT) were converted to Lys
(AAG and AAA respectively). Similarly C-sACE was gen-
erated by mutating sites His959 (CAC) and His963 (CAC)
to Lys (AAA and AAG respectively). Both constructs have
the complete signal, transmembrane and stalk region corre-
sponding to full-length sACE. The CC-sACE was con-
structed in our group as previously described [55]; briefly, it
consists of two C-domains joined by the sACE interdomain
linker region as well as the juxtamembrane stalk and trans-
membrane region in the mammalian expression vector
pLEN (Metabolic Biosystems, Mountain View, CA, USA)
(Fig. 1).
Expression and purification of enzymes
All enzymes were expressed in CHO cells using standard
tissue culture approaches as formerly described [66]. All
enzymes were purified using lisinopril-sepharose affinity
chromatography as previously described [67] with the fol-
lowing considerations: single domains were isolated from
the harvest medium while full-length enzymes were puri-
fied from whole cell triton lysates. N-domain constructs
required the addition of 800 mM NaCl to medium/lysates
for effective purification [68]. ACE activity was detected
using the substrate Cbz-Phe-His-Leu [69] and pooled
enzyme was dialysed twice with 2 L of 5 mM Hepes (pH
7.5). All enzymes were concentrated and stored at 4 °C
in 50 mM Hepes (pH 7.5). Enzyme integrity and purity
were assessed by SDS/PAGE and subsequent Coomassie
staining.
In order to determine loss of enzymatic activity due to
storage, specific activities were calculated immediately after
purification. It was assumed that enzyme which is eluted
off the lisinopril column must be active in order to bind
the ligand. Specific activities were then redetermined prior
to kinetic analysis and protein concentrations adjusted
accordingly.
Amyloid kinetics
ACE and Ab(1–16) (H-DAEFRHDSGYEVHHQK-OH)
(Bachem AG) hydrolysis assays were performed in reac-
tion tubes and transferred to HPLC vials for analysis
using the Agilent 1260 Infinity HPLC. Mixtures were sep-
arated on a Poroshell 120 EC-18 column with a 2.7 lm
pore size. The reaction consists of 25 lL substrate incu-
bated with 25 lL enzyme for 15 min at 37 °C and was
stopped with the addition of 10 lL of 0.25% trifluo-
roacetic acid (TFA). The total reaction (60 lL) was
cleared of contaminants on a spin column (GHP Nano-
sep MF Centrifugal Device 0.45 lm pore size) and run
on the HPLC. Kinetic parameters were determined
through the fitting of initial rates to the Michaelis–Menten
equation with GRAPHPAD PRISM software (v 4.01, GraphPad
Prism).
Fluorogenic substrates designed around the established
N-terminal Asp7-Ser8 cleavage site of the full-length Ab(1–
42) were used to develop a higher throughput assay. There
are two variations of the short fluorogenic peptides: Ab(4–
10)Q (Abz-FRHDSG(Q)-EDDnp) which has an N-terminal
Abz donor and a C-terminal EDDnp quencher group
attached to an additional Gln residue. The second peptide,
Ab(4–10)Y (Abz-FRHDSG-(NT)) has a different quencher
molecule, NT, which substitutes for the naturally occurring
Tyr residue.
Determination of cleavage site
Kinetic reaction digests, 24 h digests and undigested Ab(1–16)
samples were collected off the HPLC, dried down with
the Savant SpeedyVac (ThermoScientific, USA) and then
resuspended in 50% acetonitrile (ACN) prior to being sent
for mass spectrometry. The Ab(4–10)Q and Ab(4–10)Y
digested and undigested samples were cleaned over a C18
Zip Tip (Millipore) and sent for mass spectrometry. The
mass spectrometry was analysed at the Centre for
Proteomic and Genomic Research (Cape Town, South
Africa). Briefly, the collected peptides were spotted
onto a 10 mgmL1 a-cyano-4-hydroxycinnamic acid
matrix (Fluka, USA) in 80% ACN, 0.2% TFA for a final
concentration of 5 mgmL1 matrix in 40% ACN, 0.1%
TFA, 10 mM NH4H2PO4. Mass spectrometry was per-
formed with a 4800 MALDI-TOF/TOF (Applied Biosy-
tems) with all spectra recorded in positive reflector mode.
Spectra were generated with 400 laser shots/spectrum at a
laser intensity of 3800 (arbitrary units) with a grid voltage
of 16 kV.
Determination of kinetic parameters
Ab(1–16)
Enzyme reactions were initiated on the addition of 25 lL
enzyme (at a final concentration within 10% hydrolysis
of total substrate; see Table 1) to 25 lL Ab(1–16) in
Hepes buffer (50 mM Hepes pH 7.5, 100 mM NaCl,
10 lM ZnSO4 buffer), ranging in concentration from 0 to
45 lM. The reaction was incubated for 15 min at 37 °C
and stopped with the addition of 10 lL 0.25% TFA to
make up a total volume of 60 lL. The reactions were
performed in triplicate and 50 lL injections were anal-
ysed via HPLC (Agilent Technologies) across a gradient
of 0.1% TFA and 2% ACN in water to 0.1% TFA,
95% ACN. A calibration curve was set up to convert
the product peak area to picomoles product formed,
1071The FEBS Journal 283 (2016) 1060–1076 ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
K. M. Larmuth et al. The cooperativity of ACE towards Ab
through the complete hydrolysis of the substrate with the
N-domain. The initial rates of reactions were generated
by converting and plotting the resultant peak product
area, and were used to assess enzyme activity. Kinetic
constants were calculated using the Michaelis–Menten
method using GRAPHPAD PRISM software (v 4.01, Graph-
Pad Prism).
Ab(4–10)Q
Hydrolysis of the fluorogenic peptide Abz-FRHDSG(Q)-
EDDnp (Ab(4–10)Q, obtained from A. Carmona, Universi-
dade Federal de S~ao Paulo, Brazil) was performed in
Hepes buffer (50 mM Hepes pH 7.5, 100 mM NaCl, 10 lM
ZnSO4 buffer) with 150 lL enzyme (at final concentrations
within 10% hydrolysis of total substrate; see Table 2) and
equal volume of substrate ranging from 0 to 30 lM. The
assay is a modified form of the continuous assay [7] where
the assay is set up on ice in triplicate in a 96-well plate.
The baseline fluorescence was at time zero and then the
substrate was incubated at 37 °C and fluorescence read at
the 45 min time point on a Cary Eclipse spectrofluorimeter
(Varian Inc.) at kex = 320 nm and kem = 420 nm. Again,
kinetic constants were calculated using the Michaelis–Men-
ten method with GRAPHPAD PRISM software (v4.01, Graph-
Pad Prism). The detected fluorescence was converted to
picamoles product formed through the slope of a calibra-
tion curve of Abz-Gly. A correction curve was also applied
to correct the data for the inner filter effect [70].
Ab(4–10)Y
An alternative fluorogenic peptide, Abz-FRHDSG-(NT)
(BIOPEPTM South Africa) was assayed, with 100 lL
enzyme and 100 lL substrate (at a final enzyme concentra-
tion within 10% hydrolysis of total substrate; see Table 3)
as above, in 96-well plates. The samples were read at the
5 min time point on a Cary Eclipse spectrofluorimeter
(Varian Inc.) at kex = 320 nm and kem = 420 nm. Kinetic
constants, inner filter effect and standard curves were calcu-
lated as above.
X-ray crystallography
The crystals of Ndom389 in complex with Ab peptides
were obtained by co-crystallization with a 2.5 mM pep-
tide. Peptides Ab(1–16) (Sigma, SCP0052), Ab(10–16)
(Sigma, SCP0031), Ab(4–10) (GenScript, RP20173), Ab
(35–42) (GenScript RP20145) and Ab(4–10)Y were used.
Crystals were grown with 1 lL of the peptide (5–
10 mgmL1 in 50 mM Hepes, pH 7.5, 0.1 mM PMSF)
mixed with an equal volume of reservoir solution consist-
ing of 30% PEG 550 MME/PEG 20000, 100 mM Tris/
Bicine, pH 8.5, and 0.06 M divalent cations (Molecular
Dimensions) and suspended above the well as a hanging
drop. Crystals of better quality were obtained after two
to three cycles of macro-seeding.
X-ray diffraction data were collected on station IO3 at
the Diamond Light Source (Didcot, UK). Crystals were
kept at constant temperature (100 K) under the liquid
nitrogen jet during data collection. Images were collected
using a PILATUS-6M detector (Dectris, Switzerland). Raw
data images were processed and scaled with MOSFLM [71]
and SCALA using the CCP4 suite 6.5 [72]. Initial phases for
structure solution were obtained using the molecular
replacement routines of the PHASER program [73]. The
atomic coordinates of N-domain (PDB code 3NXQ [47])
were used as a search model for structure determination.
The resultant models were refined using REFMAC5 [74].
Manual adjustments of the model were carried out using
COOT [75]. Water molecules were added at positions where
Fo  Fc Fourier difference electron density peaks exceeded
3r and potential hydrogen bonds could be made. Valida-
tion was conducted with the aid of the program MOLPRO-
BITY [76]. Crystallographic data statistics are summarized in
Table 6. All figures were drawn with PYMOL (Schr€odinger,
LLC, New York, USA). Hydrogen bonds were verified
with the program LIGPLOT+ [77].
Statistical analysis
Statistical analysis of the data was determined by Student’s
t test. Differences with P < 0.05 were considered statisti-
cally significant. Fractional error was calculated for the
kcat/Km ratio with the following equation:
DZ ¼ Z
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Da
a
 2
þ Db
b
 2s
where Z represents the mean kcat/Km and DZ repre-
sents the fractional error. The Da represents the SEM
of the mean kcat (a). Similarly, Db represents the SEM
of the mean Km (b).
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